NMOSD: Differentiating New Advances in the Diagnostic and Treatment...

110 East 2nd Street,Austin TX 78701

15 February, 2022

Description

CME Lunch Symposium This program is intended for the 48th Annual Meeting, NANOS 2022 attendees only. Activity ChairAndrew G. Lee, MD Chairman of Ophthalmology Blanton Eye Institute Houston Methodist Hospital Clinical Professor of Ophthalmology University of Texas Medical Branch MD Anderson Cancer Center Adjunct Professor of Ophthalmology Baylor College of Medicine Houston, TX Professor of Ophthalmology, Neurology, and Neurosurgery Weill Cornell Medical College New York, NY Clinical Professor of Ophthalmology University of Buffalo, SUNY Buffalo, NY Adjunct Professor of Ophthalmology University of Iowa Iowa City, IA FacultyJohn J. Chen, MD, PhD Professor of Ophthalmology and Neurology Mayo Clinic Rochester, MN Heather E. Moss, MD, PhD Associate Professor of Ophthalmology, Neurology & Neurological Sciences Stanford University Palo Alto, CA OverviewNeuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune disease of the central nervous system that mainly manifests through recurrent attacks of optic neuritis and longitudinally extensive transverse myelitis. Early stages are frequently misdiagnosed. The application of newer diagnostic criteria may facilitate earlier and more accurate diagnosis by assisting neuro-ophthalmologists in the identification of individuals who might otherwise have been diagnosed with idiopathic transverse myelitis, idiopathic optic neuritis, or atypical multiple sclerosis. Treatment options have been limited until recently. Monoclonal antibodies have been used for patients with autoimmune disorders for several years, and their efficacy and safety in patients with NMOSD have been demonstrated. In this educational activity, expert clinicians discuss the burden, diagnosis pathophysiology, and treatment of NMOSD as well as a challenging case. Agenda12:10 PM Registration and Lunch 12:25 PM Introduction and Pretest Andrew G. Lee, MD 12:30 PM NMOSD: A Diagnostic Dilemma Heather E. Moss, MD, PhD 12:40 PM  Differentiating Therapeutic Options for NMOSD: Applying Evidence to Practice John J. Chen, MD, PhD 1:00 PM  Panel Discussion With Case Presentation – Treatment of NMOSD Moderated by Andrew G. Lee, MD 1:10 PM  Posttest and Question & Answer 1:25 PM Conclusion Learning ObjectivesUpon successful completion of this activity, participants should be better able to: Summarize evidence-based criteria that aids in early detection and staging of NMOSD. Differentiate the mechanisms of action of currently available NMOSD therapeutics to better understand how they can be utilized in individual patients. Assess current evidence pertaining to the safety and efficacy of monoclonal antibodies used in the treatment of NMOSD, including their ability to control acute attacks and prevent future relapses. Target AudienceThe intended audience for this activity is neuro-ophthalmologists, ophthalmologists, neurologists, and other health care professionals involved in the management of patients with NMOSD. This continuing medical education activity is provided by Vindico Medical Education. This activity is supported by an educational grant from Genentech, a member of the Roche Group. This symposium is organized by Vindico Medical Education with grant support from Genentech. NANOS is not the CME provider for this activity. Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Vindico Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to satisfy the Lifelong Learning and Self-Assessment requirements for the American Board of Ophthalmology’s Continuing Certification program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting credit. Upon successful completion, learners who opt-in by providing their ABO ID and DOB (MM/DD) will earn Continuing Certification credits equivalent to the amount of CME credits claimed for the activity Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will be mitigated prior to the commencement of the activity. Faculty, topics, program schedule, and credit hours are subject to change. Recording of any manner is prohibited without written permission from Vindico Medical Education, Office of Medical Affairs and Compliance. Contact Us: Email: [email protected] Toll-free: 888-960-0256 Ext. 219 or 476 Outside the U.S.: +(1) 856-994-9400 Ext. 219 or 476 Privacy Policy Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086